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Background. Although cognitive behavioural therapy (CBT) is claimed to be eﬀective in schizophrenia, major de-
pression and bipolar disorder, there have been negative ﬁndings in well-conducted studies and meta-analyses have
not fully considered the potential inﬂuence of blindness or the use of control interventions.
Method. We pooled data from published trials of CBT in schizophrenia, major depression and bipolar disorder that
used controls for non-speciﬁc eﬀects of intervention. Trials of eﬀectiveness against relapse were also pooled, in-
cluding those that compared CBT to treatment as usual (TAU). Blinding was examined as a moderating factor.
Results. CBT was not eﬀective in reducing symptoms in schizophrenia or in preventing relapse. CBT was eﬀective in
reducing symptoms in major depression, although the eﬀect size was small, and in reducing relapse. CBT was in-
eﬀective in reducing relapse in bipolar disorder.
Conclusions. CBT is no better than non-speciﬁc control interventions in the treatment of schizophrenia and does not
reduce relapse rates. It is eﬀective in major depression but the size of the eﬀect is small in treatment studies. On
present evidence CBT is not an eﬀective treatment strategy for prevention of relapse in bipolar disorder.
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Introduction
Cognitive behavioural therapy (CBT) has been widely
adopted by psychiatry in recent years, but its increase
in use in the severe disorders of schizophrenia, major
depression and bipolar disorder is particularly note-
worthy. This is because it challenges what has, until
recently, been a dominance of biological approaches
to these disorders. Thus, although contemporary ac-
counts of schizophrenia (e.g. Picchioni & Murray,
2007) emphasize biological factors in its aetiology and
consider neuroleptic drugs to be the mainstay of
treatment, oﬃcial UK treatment guidelines from the
National Institute for Clinical Excellence (NICE) also
state that psychological interventions are indispens-
able and that CBT should be oﬀered to all patients
(NICE, 2003, 2009). Psychological factors may loom
larger in the aetiology of major aﬀective disorder, but
when it comes to treatment, the emphasis in the
literature, particularly in bipolar disorder, has once
again been ﬁrmly on pharmacotherapy. Attitudes may
be changing here too, however. References to the ef-
fectiveness of CBT are pervasive in the UK depression
treatment guideline (NICE, 2004) ; a government in-
itiative is under way in the UK to provide CBT for
depression and anxiety in 250 dedicated therapy cen-
tres (Layard, 2006) ; and CBT is being advocated for
relapse prevention in bipolar disorder (e.g. Scott &
Colom, 2005; Basco & Rush, 2007).
Nevertheless, a cursory look at the literature reveals
well-conducted trials where CBT has had negative
ﬁndings in all three disorders. For example, large-scale
trials of CBT in schizophrenia have failed to ﬁnd
signiﬁcant advantages over befriending (Sensky et al.
2000) or supportive counselling (Lewis et al. 2002).
In depression, the National Institute of Mental Health
(NIMH) study of brief psychotherapeutic inter-
ventions found only marginal evidence for the eﬀec-
tiveness of interpersonal psychotherapy and none for
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cognitive therapy (Elkin et al. 1989). A recent large trial
of CBT for prevention of relapse in bipolar disorder
found no advantage over treatment as usual (TAU)
(Scott et al. 2006). In fact, the perceived eﬃcacy of CBT
in all three disorders seems to rest principally onmeta-
analysis, where it has been concluded, for example,
that : ‘The positive results … can therefore be taken
as conﬁrming the promise of cognitive behavioural
treatment in schizophrenia ’ (Pilling et al. 2002) ; ‘cog-
nitive therapy has been demonstrated eﬀective in
patients with mild or moderate depression and its ef-
fects exceed those of antidepressants ’ (Gloaguen et al.
1998) ; and ‘the use of psychological therapies as an
adjunct to medication [in bipolar disorder] is likely to
be clinically and cost eﬀective ’ (Scott et al. 2007).
A feature of these and other meta-analyses, how-
ever, is the lack of consideration they have given to
bias caused by lack of blinding and the failure to use a
control intervention. For example, out of seven meta-
analytical reviews of CBT for schizophrenia (Gould
et al. 2001 ; Rector & Beck, 2001; Pilling et al. 2002 ;
Jones et al. 2004 ; Tarrier & Wykes, 2004 ; Zimmermann
et al. 2005 ; Wykes et al. 2008), only two (Zimmermann
et al. 2005; Wykes et al. 2008) examined the inﬂuence of
blindness on eﬀect size, and neither of these attempted
to establish the treatment’s eﬀectiveness in trials that
used both blinding and a control intervention. Nor
was blindness addressed in either of the two bench-
mark meta-analyses of CBT for depression (Gloaguen
et al. 1998 ; Churchill et al. 2001). The way in which
CBT was compared against other psychological inter-
ventions in Gloaguen et al.’s (1998) meta-analysis has
also been criticized (Parker et al. 2003).
Noting that there is increasing evidence that in-
adequate quality of trials can translate into biased
ﬁndings of systematic reviews in health care, Ju¨ni
et al. (2001) recommended that the inﬂuence of study
quality should be examined routinely. They also
argued that it is preferable to do this by examining the
inﬂuence of key components of methodological quality
individually rather than by means of summary scores
from quality scales, which are problematic for several
reasons. This meta-analysis therefore examines the
eﬀectiveness of CBT in studies that have attempted to
guard against two of the most familiar and important
sources of bias in treatment trials, lack of blinding and
failure to use a control intervention.
Method
We included studies that examined the eﬀectiveness of
CBT in adults (i.e. not adolescents or elderly subjects)
meeting any diagnostic criteria for schizophrenia
(some of which also allowed patients with schizo-
aﬀective disorder and delusional disorder), major
depression or bipolar disorder. CBT was deﬁned as an
intervention whose core elements include the recipient
establishing links between their thoughts, feelings and
actions and target symptoms; correcting mispercep-
tions, irrational beliefs and reasoning biases related to
these target symptoms, involving monitoring of one’s
own thoughts, feelings and behaviours with respect
to the symptom; and/or the promotion of alternative
ways of coping with target symptoms.
The studies were required to use a control inter-
vention that the study investigators either explicitly
considered not to have speciﬁc therapeutic eﬀects or
which might reasonably be regarded as lacking these
(e.g. supportive therapy, psycho-education, relax-
ation). We also included studies comparing CBT to pill
placebo (which have only been carried out in major
depression). Blindness of evaluations was not speci-
ﬁed as a requirement for inclusion, but was examined
as a moderator variable. In keeping with the general
approach of meta-analysing methodologically rigor-
ous trials, we did not include studies with small
sample sizes (<10 participants in either group) or
studies that were identiﬁed by the authors as pilot
studies. Excluded studies are given as Supplementary
material (available in the online version of the paper).
We also meta-analysed studies of CBT for preven-
tion of relapse, even though many of these used TAU
as the comparison condition rather than a control
intervention. This was on grounds that (a) relapse is a
relatively objective outcome measure that should be
robust to the eﬀects of subject and observer bias ; and
(b) relapse prevention has been a major focus of stu-
dies of CBT in depression and constitutes the only
type of study that has been carried out in bipolar dis-
order. Nevertheless, we also examined the use of
TAU or a control intervention as a moderator variable,
where possible, in these studies. To be included,
studies had to use a symptomatic deﬁnition of relapse,
rather than simply equating this with rehospitaliz-
ation, and had to deﬁne relapse according to predeter-
mined criteria.
Studies were searched using existing comprehen-
sive meta-analyses of CBT for schizophrenia (Jones
et al. 2004), depression (Gloaguen et al. 1998; Churchill
et al. 2001 ; Vittengl et al. 2007) and bipolar disorder
(Scott et al. 2007), supplemented by electronic searches
of the literature (Medline, EMBASE and PsycINFO).
For the electronic search, we chose inception dates of
5 years before the publication of the earliest of the
above meta-analyses, which would have captured
earlier studies. The search was conducted up to the
end of January 2009. Review articles and the reference
lists of all obtained papers were checked, as were
research databases for trials. Only published studies
were included. There were no restrictions on year of
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publication or language. Tables A1 and A2 in the
Appendix provide details on the included studies.
Data were synthesized using standard meta-
analytical techniques. Studies comparing the eﬀect of
CBT against a control intervention were pooled from
continuous measures (i.e. symptom scores) using an
eﬀect size measure, Cohen’s d (Hedges’ correction was
used). The end-point was the end of the acute treat-
ment phase as deﬁned by the investigators. In line
with common meta-analytical practice, eﬀect sizes
obtained from a range of diﬀerent symptom rating
scales were pooled; we did not attempt to carry out
separate analyses for the diﬀerent scales, unless there
were fundamental conceptual diﬀerences between
them (e.g. self-rated versus observer-rated). Odds
ratios (ORs) were calculated for relapse rates. Fixed-
eﬀects analysis was used in both cases (random ef-
fects analyses gave similar results). Intention-to-treat
analysis was used if relevant data were available
(typically in relapse studies) or, if not, on the numbers
remaining at the end of the study period. Two of the
investigators extracted eﬀect sizes and ORs by con-
sensus. All results were checked twice. Heterogeneity
was assessed by means of the Q-statistic.
Results
Schizophrenia
Eﬀectiveness on symptoms
Nine trials were found. We excluded two studies of
ﬁrst-episode psychosis (Jackson et al. 2008 ; Lecomte
et al. 2008) because they both contained a high pro-
portion of patients (>20%) with aﬀective psychotic
diagnoses. The studies were carried out on both acute
and chronic patients and the period of treatment
ranged from 5 weeks to 9 months. The control in-
terventions used were supportive counselling/sup-
portive therapy (n=5), befriending (n=1), group
psycho-education (n=1), recreational therapy (n=1)
and social activity therapy (n=1). Two were open
studies and seven were carried out under blind
conditions. Several studies did not provide overall
symptom scores but instead gave separate scores for
positive and negative symptoms (and sometimes dis-
organization or general psychopathology). To max-
imize the number of usable studies, therefore, a
combined eﬀect size for all symptoms for each study
was ﬁrst calculated by averaging the eﬀect sizes for
these symptoms (this was done using the individual
eﬀect sizes and standard errors, using a random eﬀects
model and testing for homogeneity in each case).
Eﬀects on positive and negative symptoms were then
examined separately.
The ﬁndings are shown in Fig. 1. The pooled eﬀect
size wasx0.08 [95% conﬁdence interval (CI)x0.23 to
+0.08, p=0.34] (the negative sign favours CBT). The
studies were not signiﬁcantly heterogeneous [Q(8)=
9.28, p=0.32]. As Fig. 1 suggests, the two non-blind
studies had a signiﬁcantly larger pooled eﬀect size
than the seven blind studies (x0.63 v. 0.00) [QB(1)=
6.38, p=0.01]. Dividing studies into those carried out
on acute patients (n=1), mixed or unspeciﬁed patients
(n=6) and chronic patients (n=2) did not reveal dif-
ferences [eﬀect size +0.10, x0.17 and x0.04 respect-
ively, QB(2)=1.82, p=0.40]. The overall eﬀect size was
increased only slightly by excluding the single study
that used a group therapy form of CBT (Bechdolf et al.
2004) (eﬀect size for eight studies=x0.11, 95% CI
x0.29 to+0.06, p=0.19).
Eight studies reported ﬁndings for positive symp-
toms and seven for negative symptoms. The pooled
Study
(1st-named author)
Statistics for each study
Sample size
Hedges'  g and 95% CI
Hedges'
g
Upper
limitlimit CBT Control
Drury (1996) –0.543 –1.162 0.076 20 20
Pinto (1999) –0.718 –1.370 –0.067 19 18
Tarrier (1999)* –0.264 –0.848 0.319 23 21
Sensky (2000)* –0.084 –0.494 0.326 46 44
Lewis (2002)* 0.097 –0.223 0.417 78 71
Durham (2003)* 0.058 –0.544 0.660 22 19
Bechdolf (2004)* 0.172 –0.251 0.596 39 46
Valmaggia (2005)* 0.061 –0.458 0.580 35 23
Haddock (2009)* –0.235 –0.749 –0.279 28 29
–0.076 –0.235 0.084
–1.00 –0.50 0.00 0.50 1.00
Favours CBT Favours control
Lower
Fig. 1. Studies of the eﬀectiveness of cognitive behavioural therapy (CBT) against symptoms in schizophrenia
(* indicates blind study).
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eﬀect size for positive symptoms was x0.19 (95% CI
x0.37 tox0.02, p=0.03), favouring CBT. Once again,
however, the result was moderated by blindness : the
eﬀect size in the six blind studies wasx0.08 compared
to x0.87 in the two non-blind studies [QB(1)=9.28,
p=0.002]. The pooled eﬀect size for negative symp-
toms was x0.02 (95% CI x0.22 to +0.18) ; here,
blindness did not moderate the eﬀect size [eﬀect size
for ﬁve blind studies+0.04 v.x0.26 for two non-blind
studies, QB(1)=1.36, p=0.24].
Eﬀectiveness against relapse
Eight studies were found. These had follow-up
periods of 6 months to 3 years. We did not include two
studies (Drury et al. 2000 ; Turkington et al. 2008) be-
cause there was a 5-year interval between treatment
and assessment during which there was no inter-
vention or evaluation. Three of the studies compared
CBT against TAU, and ﬁve included comparison
groups of supportive counselling. Six rated relapse
under blind conditions and two under non-blind con-
ditions. The studies deﬁned relapse in terms of in-
creases in positive symptoms, usually requiring that
the increase lasted a speciﬁed period and sometimes
with a requirement of hospitalization or change in
management (see Appendix).
The ﬁndings are shown in Fig. 2. The pooled OR for
these studies was 1.17 (95% CI 0.88–1.55, p=0.29),
non-signiﬁcantly favouring TAU. The studies were
not signiﬁcantly heterogeneous [Q(7)=11.89, p=0.10].
Blindness moderated the eﬀect size at trend level [OR
for six blind studies 1.35 v. 0.72 for two non-blind
studies, QB(1)=3.28, p=0.07]. However, use of control
intervention was not a signiﬁcant moderating factor
[QB(1)=0.02, p=0.89]. Once again, there was nothing
to suggest that inclusion of studies using group CBT
was inﬂuencing the result [OR for six studies using
individual CBT 1.12 v. 1.01 for two studies using
group CBT, QB(1)=0.20, p=0.66].
In the study of Garety et al. (2008a) we analysed re-
lapse data in patients who had made a full or partial
recovery. However, Garety et al. (2008b) have argued
that these rates do not reﬂect the true intention-to-treat
eﬀect because patients were randomized to CBT or
TAU while they were ill ; some failed to recover (CBT,
n=9; TAU, n=18) and so did not have the oppor-
tunity to relapse. Adjusting the total numbers for CBT
and TAU to include patients who were randomized
but did not recover made little diﬀerence to the pooled
OR (1.20, 95% CI 0.91–1.59, p=0.19).
Major depression
Eﬀectiveness against symptoms
Ten studies were found. These all excluded patients
with bipolar disorder or psychotic depression. Six
of the studies compared patients against a control
psychological intervention and four against pill
placebo. The studies all measured symptoms using
the observer-rated Hamilton Depression Rating Scale
(HAMD) or the self-rated Beck Depression Inventory
(BDI), or both. Because the former scale is observer
rated and the latter a self-rating questionnaire, we
meta-analysed data from these scales separately.
Figure 3 shows the result for the nine studies using
the HAMD. The pooled eﬀect size was x0.28 (95%
CI x0.45 to x0.12, p=0.001), signiﬁcantly favouring
CBT. The studies were not heterogeneous [Q(8)=9.40,
p=0.31]. The eﬀect size was signiﬁcantly greater in
the four studies comparing CBT to pill placebo than in
the ﬁve comparing it to control psychological inter-
vention [x0.41 v. 0.00, QB(1)=4.94, p=0.03]. Blind-
ness of evaluations did not signiﬁcantly moderate the
Study
(1st-named author)
Relapse/ Total
Odds ratio and 95% CI
Odds
ratio
Upper
limit CBT Control
Hogarty (1997) 1.572 0.633 3.906 14/48 11/53
Tarrier (1999)* 1.500 0.358 6.285 6/23 4/21
Gumley (2003) 0.414 0.191 0.896 13/72 25/72
Bechdolf (2004)* 0.543 0.150 1.962 4/39 8/46
Tarrier (2004)* 1.108 0.629 1.951 53/97 50/96
Valmaggia (2005)* 1.333 0.114 15.612 2/35 1/23
Barrowclough (2006)* 1.297 0.572 2.940 18/55 15/55
Garety (2008a)* 1.841 1.096 3.092 60/122 41/119
1.167 0.879 1.548
0.01 0.1 1 10 100
Favours CBT Favours control
Lower
limit
Fig. 2. Studies of the eﬀectiveness of cognitive behavioural therapy (CBT) in reducing relapse in schizophrenia
(* indicates blind study).
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eﬀect size in these studies [pooled eﬀect size for
ﬁve blind studies x0.39 v. x0.16 in three non-blind
studies ; QB(1)=1.00, p=0.32] (the study of Scott and
Freeman, 1992 was excluded from this analysis be-
cause of uncertainty over whether blindness had been
maintained).
The pooled eﬀect size for the eight studies using the
BDI was similar at x0.27 (95% CI x0.45 to x0.08,
p=0.004). Use of psychological control intervention
(ﬁve studies) or pill placebo (three studies) did not
moderate the eﬀect size in these studies (x0.27 v.
x0.27). The BDI is a self-rated scale and so none of
these studies could be considered blind.
Eﬀectiveness against relapse
Nine studies were included. We excluded four studies
(Evans et al. 1992 ; Hollon et al. 2005 ; Segal et al. 2006 ;
Dobson et al. 2008) because of systematic bias : the
patients in the control group, but not those in the CBT
group, had been treated with antidepressant medi-
cation until immediately before withdrawal at the
start of the study, so potentially increasing the risk of
depressive relapse in this group. All but one of the
studies compared CBT to TAU (Perlis et al. 2002 com-
pared it to pill placebo), and in all but one cases
relapse was determined by an assessor who was
blind to allocation. Relapse was typically deﬁned as
development of symptoms meeting diagnostic criteria
for major depression ; however, three studies allowed
a supplementary criterion based on development of
depressive symptoms exceeding a predetermined
threshold but not meeting criteria for major depression
(Shea et al. 1992 ; Paykel et al. 1999 ; Perlis et al. 2002).
The studies are summarized in Fig. 4. The pooled
OR was 0.53 (95% CI 0.40–0.71, p<0.001). The studies
were not signiﬁcantly heterogeneous [Q(7)=8.60, p=
0.38]. All, or nearly all, of the studies were blind
(blindness was not commented on in the study of Shea
et al. 1992), and all but one (Perlis et al. 2002) compared
CBT to TAU. Therefore, these moderating variables
were not examined.
In two studies patients in both groups remained on
antidepressant medication throughout the follow-up
period, whereas in ﬁve, both groups were withdrawn
from medication either before study entry or within
the ﬁrst 20 weeks of a 2-year follow-up (in the other
two studies some patients in both groups were
treated). The pooled ORs for studies on treated and
untreated patients were 0.52 and 0.45 respectively
[QB(1)=0.17, p=0.67].
Bipolar disorder
Eﬀectiveness against relapse
There were no includable trials of CBT as a treatment
for acutely ill patients. Four controlled trials of CBT for
prevention of relapse have been carried out and are
shown in Fig. 5. They all compared CBT to TAU and
the assessments were all made under blind conditions.
In three of the studies relapse was deﬁned as devel-
opment of symptoms suﬃcient to meet diagnostic
criteria for major depression, mania, hypomania, or
a mixed state ; the fourth required a deﬁned period
of moderate/severe or incapacitating depressive or
manic symptoms. The pooled OR for the four studies
was insigniﬁcant at 0.78 (95% CI 0.53–1.15, p=0.22).
Discussion
Studies of psychological therapies in major psychiatric
disorder have not used, and perhaps will never be able
Group by
control type
Study
(1st-named author)
Statistics for each study
Sample size
Hedges' g and 95% CI
Hedges'
g
Upper
limit limit CBT Control
Control psych Miller (1989) –0.417 –1.145 0.310 14 14
Control psych Bowers (1990)* –0.116 –0.956 0.725 10 10
Control psych Beutler (1991) 0.159 –0.443 0.760 21 20
Control psych Scott (1992) 0.306 –0.205 0.817 29 29
Control psych Murphy (1995) –0.428 –1.213 0.356 11 13
Control psych –0.003 –0.298 0.291
Pill placebo Elkin (1989)* –0.317 –0.673 0.040 59 62
Pill placebo Jarrett (1999)* –0.529 –0.994 –0.064 36 36
Pill placebo DeRubeis (2005)* –0.437 –0.797 –0.077 60 60
Pill placebo Dimidjian (2006)* –0.400 –0.842 0.041 38 41
Pill placebo –0.409 –0.608 –0.210
Overall –0.282 –0.447 –0.117
–1.00 –0.50 0.00 0.50 1.00
Favours CBT Favours control
Lower
Fig. 3. Studies of the eﬀectiveness of cognitive behavioural therapy (CBT) against symptoms in major depression
(* indicates blind study).
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to use, precisely the same methodology as that used
to establish the eﬃcacy of drug treatments, namely
the double-blind, placebo-controlled trial. However,
when those studies whose design approximates to this
methodology are reviewed, their ﬁndings are at vari-
ance with the conclusions expressed in review articles,
meta-analyses, editorials and even government docu-
ments.
The contrast is at its starkest in schizophrenia. In a
recent editorial, Kingdon (2006) stated : ‘More than 20
randomized controlled trials and ﬁve meta-analyses
have shown cognitive behaviour therapy to be ben-
eﬁcial in schizophrenia, reducing both positive and
negative symptoms during therapy and beyond. ’
Yet pooling the results of nine trials comparing
CBT to non-speciﬁc control interventions reveals no
indication of eﬀectiveness. Nor does meta-analysis
of a similar-sized body of evidence of CBT for re-
lapse prevention yield any evidence of an eﬀect. CBT
for schizophrenia thus ﬁnds itself in the unusual
position of being recommended in the revised NICE
guideline (NICE, 2009), despite having failed in all
of the treatment studies that used both control inter-
ventions and blind evaluations, and after the authors
of the largest trial of relapse prevention (Garety et al.
2008a) concluded that ‘generic CBT for psychosis
is not indicated for routine relapse prevention in
people recovering from a recent relapse of schizo-
phrenia. ’
It could be objected that our meta-analysis of posi-
tive symptom scores revealed a small but signiﬁcant
eﬀect size [x0.19 (95% CI x0.37 to x0.02), p=0.03]
in favour of CBT. However, this advantage seemed
clearly to reﬂect the lack of blindness of two of
the trials ; CBT showed no evidence of eﬀectiveness
against positive symptoms in the pooled results from
six trials that used both control interventions and
blind evaluations. Another ground for appeal might
be that one relatively large study of the eﬀectiveness
of CBT in schizophrenia (Sensky et al. 2000) found
Study
(1st-named author)
Relapse/Total
Odds ratio and 95% CI
Odds Upper
limitratio limit CBT Control
Shea (1992) 1.071 0.288 3.985 9/23 6/16
Fava (1994)* 0.357 0.078 1.627 3/21 7/22
Fava (1998)* 0.104 0.027 0.408 5/23 16/22
Paykel (1999)* 0.473 0.244 0.916 23/80 35/76
Teasdale (2000)* 0.571 0.290 1.124 31/71 38/66
Jarrett (2001)* 0.655 0.271 1.583 14/41 19/43
Perlis (2002)* 0.787 0.202 3.071 4/66 5/66
Ma (2004)* 0.387 0.151 0.995 14/36 23/37
Bockting (2005)* 0.682 0.370 1.259 49/88 54/84
0.533 0.398 0.715
0.01 0.1 1 10 100
Favours CBT Favours control
Lower
Fig. 4. Studies of the eﬀectiveness of cognitive behavioural therapy (CBT) in reducing relapse in major depression
(* indicates blind study).
Study
(1st-named author)
Relapse/ Total
Odds ratio and 95% CI
Odds Upper
ratio limit limit CBT Control
Lam (2003)* 0.311 0.138 0.700 21/51 36/52
Ball (2006)* 0.500 0.141 1.772 5/25 9/27
Scott (2006)* 1.082 0.661 1.772 67/127 64/126
Zaretsky (2008)* 1.544 0.400 5.958 6/40 4/39
0.785 0.535 1.152
0.01 0.1 1 10 100
Favours CBT Favours control
Lower
Fig. 5. Studies of the eﬀectiveness of cognitive behavioural therapy (CBT) in reducing relapse in bipolar disorder
(* indicates blind study).
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that, although CBT was no better than a control inter-
vention of befriending at the end of the 9-month
treatment period, it did show a signiﬁcant advantage
at follow-up a further 9 months later. However, de-
layed or enduring eﬀects have not been observed in
other studies (Tarrier et al. 1999, 2004), and the most
recent meta-analysis (NICE, 2008) found eﬀect sizes
for CBT against ‘active controls ’ (mainly non-speciﬁc
control interventions, but in one case cognitive re-
mediation therapy) of only x0.18 (95% CI x0.39
to +0.03, ﬁve studies) at 12-month follow-up and
x0.08 (95% CI x0.40 to +0.24, three studies) at 24
months.
A ﬁnal objection could be that, in the meta-analysis
of relapse rates, we did not include studies that used
hospitalization as an index of relapse. This decision
excluded a large study which found that CBT signiﬁ-
cantly reduced the rate of subsequent hospitalization
in schizophrenia (Turkington et al. 2006). The NICE
(2009) meta-analysis of this and four other studies also
found a signiﬁcant advantage for CBT in reducing re-
hospitalization (relative risk 0.76, 95% CI 0.61–0.94).
Nevertheless, hospitalization is not the same thing as
relapse ; the decision to admit a schizophrenic patient
depends not only on their clinical status but also on
considerations of whether there is support outside
hospital, whether the patient is likely to comply with
treatment at home, etc., judgements of which could
be inﬂuenced by knowledge that he or she is in the
active treatment arm of a trial. Indeed, the fact that
Turkington et al.’s (2006) trial, where hospitalization
was the outcome measure, and Garety et al.’s (2008a)
similarly large trial, where relapse was the outcome
measure, had such completely contradictory results
attests to the reality of the diﬀerence between these
two measures.
However, CBT does emerge from our meta-
analytical review as an eﬀective treatment for major
depression, both as a treatment for acute symptoms
and for relapse prevention. Nevertheless, there is a
qualiﬁcation to this conclusion: at 0.28 (HAMD) and
0.27 (BDI) the pooled eﬀect size for the acute treatment
studies was in the small range, implying only modest
therapeutic beneﬁt. These ﬁndings bear comparison
with those of the most exhaustive meta-analysis
of psychological treatments for depression to date,
the National Health Service (NHS) R&D Health
Technology Assessment systematic review of brief
psychological treatments for depression (Churchill
et al. 2001). This found that all of a range of psycho-
therapeutic interventions showed signiﬁcant advan-
tages when compared to TAU or a waiting list control.
CBT was also found to be signiﬁcantly superior to
supportive therapy. However, here the authors went
on to state : ‘The overall quality score of the trials
appeared to have a considerable eﬀect on recovery
and mean diﬀerences, with lower-scoring trials dem-
onstrating a pronounced and highly signiﬁcant dif-
ference and higher-scoring trials demonstrating no
signiﬁcant diﬀerences. ’ Perhaps, more than anything
else, our review makes it clear that a large, method-
ologically rigorous trial comparing CBT to a non-
speciﬁc control intervention in depression, similar to
the several that exist in schizophrenia, has yet to be
carried out. We were able to ﬁnd only ﬁve such
studies, all of which were small and only one of which
was carried out under blind conditions. This might
be considered a somewhat slender evidence base on
which to introduce 250 treatment centres providing
CBT for depression and anxiety across the UK.
For understandable reasons, little work has ex-
amined the usefulness of CBT in patients who are
acutely manic or hypomanic. However, pilot studies
(Lam et al. 2000 ; Scott et al. 2001) gave grounds for
optimism for its use in relapse prevention. Three out
of the four formal trials then went on to ﬁnd no sig-
niﬁcant advantage for CBT, including one with very
large numbers (n=253). Meta-analysis of these trials
supports the conclusion that this form of psycho-
logical therapy is ineﬀective in preventing relapse in
bipolar disorder.
A certain amount of ambiguity concerning the
nature of control interventions is evident in the meta-
analytical literature on CBT. Sometimes the term
‘active control ’ is used (e.g. NICE, 2009), with the im-
plication, not always correct, that, similar to how the
term is used in drug studies, the therapy is being
compared against an intervention that also has estab-
lished therapeutic beneﬁts. In other meta-analyses, a
strategy is adopted of evaluating CBT systematically
against a range of diﬀerent therapies, some of which,
such as relaxation and supportive counselling, would
be expected to have little or no therapeutic eﬀect,
whereas others, such as psychodynamic therapy, have
clear therapeutic aims (e.g. Churchill et al. 2001 ;
Cuijpers et al. 2008). However, it is important not to
lose sight of the fact that we only included studies
using control interventions that lacked any speciﬁc
therapeutic eﬀect. Thus, for example, Sensky et al.
(2000) described befriending as a non-speciﬁc control
intervention, whose beneﬁts for people with schizo-
phrenia do not have any underlying theoretical or
empirical basis, where the sessions focused on neutral
topics, such as hobbies, sports and current aﬀairs,
and in which psychotic or aﬀective symptoms were
not directly tackled in any way. Similarly, Churchill
et al. (2001), in the NHS R&D Health Technology
Assessment systematic review of brief psychological
treatments for depression, deﬁned supportive therapy
as ‘an inclusive term, often used in treatment outcome
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trials to describe an attention-placebo condition to
provide a comparison to active manualized psycho-
logical interventions. ’ Certainly, these interventions
can result in symptomatic improvement, but there
is no mystery as to why this should occur. Psycho-
logical interventions are susceptible to the so-called
Hawthorne eﬀect (e.g. Gillespie, 1991), the tendency of
people singled out for a study of any kind to improve
their performance or behaviour simply because of the
special attention they receive. (The name derives from
an electricity plant in the USA where a famous series
of studies established that just about any intervention
signiﬁcantly increased the workers’ productivity.)
Should evidence from well-controlled studies out-
weigh evidence from poorly controlled ones? Until
recently the answer to this question would have been
emphatically yes ; it is a familiar story in medicine for
a treatment to show promise in one or more open
studies, and then perhaps be successful in a crossover
trial, only to go on to fail miserably in double-blind,
placebo-controlled, parallel group trials. This simple
algorithm has been complicated by meta-analysis,
which typically includes all studies, good and poor,
published and unpublished, in an eﬀort to arrive at the
best possible estimate of the size of the treatment ef-
fect. Use of such a broad-brush approach makes sub-
sequent examination of study qualities desirable, even
mandatory. Yet there seems to have been a reluctance
to do this in the meta-analytical literature on CBT in
major psychiatric illness. Even the otherwise exemp-
lary Cochrane meta-analysis of schizophrenia (Jones
et al. 2004), which carried out separate analyses of CBT
against TAU and supportive counselling, still failed
to examine the moderating eﬀect of blindness. The
authors of meta-analyses of CBT for depression seem
unperturbed by the fact that they are basing their
conclusions on studies that have often been carried out
against TAU or a waiting list control ; that have not
always been randomized; that sometimes failed to use
diagnostic criteria ; and that so far have ignored the
moderating eﬀect of blindness altogether. These issues
are not trivial ; the ﬁndings of our meta-analysis could
be viewed as an object lesson on the importance of
taking such sources of bias into account.
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Appendix. Summary of included trials
Table A1. Treatment studies
Study Sample sizes Blindness
Diagnostic
criteria
Duration of
therapy Patient type Eﬀect size (Hedges corrected)
I. Schizophrenia
Drury et al. (1996) 20 CBT Non-blind Owna 12 weeks In-patients with psychotic symptoms x0.54 (averaged)
20 recreational
therapy
Acute and chronic (Manchester positivex0.94 ; Manchester
negativex0.18)
Pinto et al. (1999) 19 CBT+SST Non-blind DSM-IV 6 months In- and out-patients with treatment-
refractory psychosis
x0.72 (BPRS)
18 supportive therapy
At least some chronic
(SAPS,x0.79, SANSx0.33)
Tarrier et al. (1999) 23 CBT Blind DSM-III-R 10 weeks Out-patients with persistent positive
symptoms
x0.26 (averaged)
21 supportive
counselling Acute and chronic
(BPRS positivex0.47, SANSx0.07)
Sensky et al. (2000) 46 CBT Blind ICD-10/
DSM-IV
9 months Patients with persistent symptoms causing
distress/dysfunction
x0.08 (CPRS)
44 befriending
Chronic
(SANS+0.07)
Lewis et al. (2002) 78 CBT Blind DSM-IV 5 weeks In- or day-patients with positive symptoms +0.10 (PANSS)
71 supportive
counselling
First or second episode (PANSS positive+0.09)
Durham et al.
(2003)
22 CBT Blind ICD-10/
DSM-IV
9 months In- and out-patients with persistent positive
symptoms
+0.06 (PANSS)
19 supportive
counselling Chronic
(PSYRATS positive+0.02 averaged)
Bechdolf et al.
(2004)
39 group CBT Blind ICD-10 8 weeks In-patients (acute admissions) +0.17 (averaged)
46 group psycho-
education
Acute and chronic (PANSS positivex0.02, PANSS negative
+0.16, PANSS general+0.39)
Valmaggia et al.
(2005)
35 CBT Blind DSM-IV 22 weeks Acute and chronic in-patients with
persistent positive symptoms
+0.06 (averaged)
23 supportive
counselling
(PANSS positivex0.30, PANSS negative
+0.36, PANSS general+0.13)
Haddock et al.
(2009)b
28 CBTc Blind DSM-IV 6 months In- and out-patients with persistent positive
symptoms
x0.23 (PANSS)
29 social activity
therapy
(PANSS positivex0.16, PANSS negative
x0.38)
II. Major depression
McLean &
Hakstian (1979)
42 CBT Non-blind Feigner 10 weeks Out-patients BDIx0.38
43 relaxation Not on drug treatment (calculated from proportion of
responders)
20
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Miller et al. (1989) 14 CBT Non-blind DSM-III 20+ weeks In-patients, continuing after discharge HAMDx0.42
14 SST On drug treatment BDIx0.14
(calculated from proportion of
responders)
Bowers (1990) 10 CBT Blind DSM-III 12 days In-patients HAMDx0.12
10 relaxation On drug treatment BDIx0.07
Beutler et al. (1991) 21 group CBT Non-blind DSM-III 20 weeks Out-patients HAMD+0.16
20 supportive, self-
directed therapy
Not on drug treatment BDIx0.48
Scott & Freeman
(1992)
29 CBT Uncertaind DSM-III 16 weeks Out-patients HAMD+0.31
29 social work
counselling
Not on drug treatment
Murphy et al.
(1995)
11 CBT Non-blind Feighner 16 weeks Out-patients HAMDx0.43
13 relaxation Not on drug treatment BDI+0.18
Elkin et al. (1989) 59 CBT Blind RDC 16 weeks Out-patients HAMDx0.32
62 pill placebo Not on drug treatment BDIx0.15
Jarrett et al. (1999)e 36 CBT Blind DSM-III-R 10 weeks Out-patients HAMDx0.53
36 pill placebo Not on drug treatment BDIx0.63
DeRubeis et al.
(2005)
60 CBT Blind DSM-IV 8 weeks Out-patients HAMDx0.44
60 pill placebo Not on drug treatment (as given by authors)
Dimidjian et al.
(2006)
38 CBT Blind DSM-IV 8 weeks Out-patients HAMDx0.40
41 pill placebo Not on drug treatment BDIx0.12
(averaged across low and
high severity groups)
CBT, Cognitive behavioural therapy ; SST, social skills training ; RDC, Research Diagnostic Criteria ; Manchester, Manchester/Krawieka scale ; BPRS, Brief Psychiatric Rating
Scale ; SAPS, Schedule for the Assessment of Positive Symptoms ; SANS, Scale for the Assessment of Negative Symptoms ; CPRS, Comprehensive Psychopathological Rating Scale ;
PANSS, Positive and Negative Syndrome Scale ; PSYRATS, Psychotic Symptom Rating Scales ; HAMD, Hamilton Depression Rating Scale ; BDI, Beck Depression Inventory.
a Used World Health Organization (WHO)-based criteria for non-aﬀective functional psychosis.
b Patients also had a history of violent behaviour.
c Patient numbers at end of study approximate as exact data not given.
d Independent evaluations, but ‘ it is likely that the patients made them aware of their treatment ’.
e Patients met DSM-III-R criteria for major depression with atypical features (maintained reactivity of mood plus two or more of hyperphagia, hypersomnia, sensation of
heaviness/leaden paralysis in limbs, lifetime sensitivity to rejection).
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Table A2. Studies of relapse prevention
Study Sample sizes Blindness
Diagnostic
criteria Relapse criteria Duration of CBT Follow-up Patient type Relapse rates
I. Schizophrenia
Hogarty et al. (1997) 48 CBT Non-blind RDC Deﬁned increase in psychotic
symptoms and clinical
consensus
Up to 3 years 3 years Acute and chronic 14/48 CBT
53 supportive
therapy
11/53 Control
Tarrier et al. (1999) 23 CBT Blind DSM-III-R Rehospitalization for clinical
deterioration resulting in
functional impairment
3 months 12 months Mainly chronic out-
patients with persistent
positive symptoms
6/23 CBT
21 supportive
counselling
4/21 Control
Gumley et al. (2003) 72 CBT Non-blind DSM-IV Hospitalization or deﬁned
increase in psychotic
symptoms
12 weeks 12 months Relapse-prone patients,
at least some chronic
13/72 CBT
72 TAU + targeted
treatment for signs
of relapse
25/72 TAU
Bechdolf et al. (2004) 39 group CBT Blind ICD-10 Deﬁned increase in psychotic
symptoms
8 weeks 6 months Relapse-prone patients,
at least some chronic
4/39 CBT
46 psycho-
education
+ continued post-
discharge
8/46 Control
Tarrier et al. (2004) 97 CBT Blind DSM-III-R Exacerbation of symptoms
lasting>1 week and leading
to change in management
5 weeks 18 months First- or second-episode
in-patients with positive
symptoms
53/97 CBT
96 supportive
counselling
+ booster sessions
up to 3 months
50/96 Control
Valmaggia et al.
(2005)
35 CBT Blind DSM-IV Deﬁned increase in positive
symptoms lasting>3 days
22 weeks 12 months Acute and chronic
patients with persistent
positive symptoms
2/35 CBT
23 supportive
counselling
1/23 Control
Barrowclough et al.
(2006)
57 group CBT Blind DSM-IV >2-week exacerbation of
symptoms requiring change
in management
6 months 12 months Patients with persistent
positive symptoms
18/55 CBT
56 TAU 15/55 TAU
Garety et al. (2008a) 122 CBTa Blind DSM-IV Re-emergence of positive
symptoms lasting>2 weeks ;
worsening of positive
symptoms to at least
moderate degree
9 months 24 months Patients with at least two
episodes of illness
60/122 CBT
119 TAU 41/119 TAU
II. Major depression
Shea et al. (1992) 23 CBT Not stated RDC RDC major depression or
receiving treatment for
depression
16 weeks 18 months Antidepressant treatment
at clinician’s discretion
9/23 CBT
16 TAU 6/16 TAU
Fava et al. (1994) 21 CBT Blind RDC RDC major depression 20 weeks 2 years Antidepressants
withdrawn over ﬁrst
20 weeks
3/21 CBT
22 TAU 7/22 TAU
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Fava et al. (1998) 23 CBT Blind RDC RDC major depression 20 weeks 2 years o3 episodes with 2 in
past 2.5 years.
5/23 CBT
22 TAU
Antidepressants
withdrawn over ﬁrst
20 weeks
16/22 TAU
Paykel et al. (1999) 80 CBT Blind DSM-III-R DSM-III-R major depression or
increasing persistent symptoms
20 weeks 1 year Patients all had residual
symptoms.
23/80 CBT
76 TAU +2 booster
sessions Antidepressants
continued throughout
study
35/76 TAU
Teasdale et al. (2000) 71 CBT Blind DSM-III-R DSM-III-R major depression 8 weeks 1 year o2 episodes in past
5 years.
31/71 CBT
66 TAU
All patients oﬀ
antidepressants for at
least 12 weeks before
study entry
38/66 TAU
Jarrett et al. (2001) 41 CBT Blind DSM-IV DSM-IV major depression 8 months 2 years o2 episodes. 14/41 CBT
43 TAU All patients drug free
from outset
19/43 TAU
Perlis et al. (2002) 66 CBT Blind DSM-III-R DSM-III-R major depression
or increase in symptoms
28 weeks 28 weeks o3 episodes in past
2.5 years ; most recent
episode chronic ; poor
interepisode recovery.
4/66 CBT
66 medication
management
Antidepressant
continued throughout
study
5/66 Control
Ma & Teasdale
(2004)
36 CBT Blind DSM-IV DSM-IV major depression 8 weeks 1 year o2 episodes in past
5 years.
14/36 CBT
37 TAU +2 booster
sessions All patients oﬀ
antidepressants for at
least 12 weeks before
study entry
23/37 TAU
Bockting et al. (2005) 88 group CBT Blind DSM-IV DSM-IV major depression 8 weeks 2 years Rates of antidepressant
treatment did not diﬀer
between groups
49/88 CBT
84 TAU 54/84 TAU
III. Bipolar disorder
Lam et al. (2003) 51 CBT Blind DSM-IV DSM-IV major depression,
mania or hypomania
6 months
+2 booster
sessions
6 months o2 episodes in past
2 years oro3 episodes
in past 5 years.
21/51 CBT
52 TAU
Patients with residual
symptoms excluded
36/52 TAU
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Table A2 (cont.)
Study Sample sizes Blindness
Diagnostic
criteria Relapse criteria Duration of CBT Follow-up Patient type Relapse rates
Ball et al. (2006) 25 CBT Blind DSM-IV DSM-IV major depression, mania,
hypomania, mixed state
6 months 6 months o1 episode in past 18
months.
5/25 CBT
27 TAU Patients with mild
symptoms included
9/27 TAU
Scott et al. (2006) 127 CBT Blind DSM-IV DSM-IV major depression, mania,
hypomania, mixed state
6 months 12 months o2 episodes of illness
(1 in past year).
67/127 CBT
126 TAU +2 booster
sessions Rapid cyclers excluded.
64/126 TAU
Patients with mild
symptoms included
Zaretsky et al.
(2008)
40 CBT+psycho-
education
Blind DSM-IV 2 weeks of moderate/severe
depressive or 1 week of
moderate/severe symptoms of
hypomania on daily mood chart
¡ hospitalization
13 weeks 12 months Bipolar I or II, not
currently in full episode
6/40
39 TAU+psycho-
education
4/39
CBT, Cognitive behavioural therapy ; TAU, treatment as usual ; RDC, Research Diagnostic Criteria.
a Numbers refer to patients who showed full or partial recovery (see text).
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